人诱导多能干细胞来源的心脏肌肉补片改善猪心肌梗死恢复
研究用 fibrin 支架悬浮人诱导多能干细胞分化的心肌细胞、平滑肌细胞和内皮细胞,在动态摇床培养下制成临床尺寸(4 cm × 2 cm × 1.25 mm)的心脏肌肉补片(hCMP),并在猪心肌梗死模型中评估。结果显示 hCMP 移植 4 周后移植率 10.9±1.8%,左心室功能、梗死面积、室壁应力、心肌肥厚和凋亡均改善,且未见心律失常发生率的显著变化。
要点
- hCMP 可在体外动态培养 7 天内成熟并同步搏动。
- 猪心梗模型中 hCMP 移植 4 周移植率为 10.9±1.8%。
- hCMP 移植改善左室功能、减小梗死面积且不增加心律失常。
核心结论
- 临床尺寸的三谱系心脏肌肉补片移植可显著减小猪心肌梗死面积并改善心脏功能,且不增加心律失常风险。
研究设计与样本
- 研究在猪心肌梗死模型中进行,分为 hCMP 组(n=13)、无细胞纤维蛋白补片组(n=14)、无补片对照组(n=15)和假手术组(n=8)。
主要发现
- hCMP 移植 4 周后移植率为 10.9±1.8%。
- hCMP 移植与左心室功能、梗死面积、心肌壁应力、心肌肥厚改善及瘢痕边缘区心肌凋亡减少相关。
- hCMP 移植逆转了部分心肌梗死相关的肌节调节蛋白磷酸化改变。
- hCMP 释放的外泌体似乎具有细胞保护特性,可改善心肌细胞存活。
- hCMP 治疗未伴随心律失常发生率的显著变化。
临床怎么用
- hCMP 移植可能作为心肌梗死后再生的治疗策略,需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Here, we generated human cardiac muscle patches (hCMPs) of clinically relevant dimensions (4 cm × 2 cm × 1.25 mm) by suspending cardiomyocytes, smooth muscle cells, and endothelial cells that had been differentiated from human induced-pluripotent stem cells in a fibrin scaffold and then culturing the construct on a dynamic (rocking) platform. METHODS: In vitro assessments of hCMPs suggest maturation in response to dynamic culture stimulation. In vivo assessments were conducted in a porcine model of myocardial infarction (MI). Animal groups included: MI hearts treated with 2 hCMPs (MI+hCMP, n=13), MI hearts treated with 2 cell-free open fibrin patches (n=14), or MI hearts with neither experimental patch (n=15); a fourth group of animals underwent sham surgery (Sham, n=8). Cardiac function and infarct size were evaluated by MRI, arrhythmia incidence by implanted loop recorders, and the engraftment rate by calculation of quantitative polymerase chain reaction measurements of expression of the human Y chromosome. Additional studies examined the myocardial protein expression profile changes and potential mechanisms of action that related to exosomes from the cell patch. RESULTS: The hCMPs began to beat synchronously within 1 day of fabrication, and after 7 days of dynamic culture stimulation, in vitro assessments indicated the mechanisms related to the improvements in electronic mechanical coupling, calcium-handling, and force generation, suggesting a maturation process during the dynamic culture. The engraftment rate was 10.9±1.8% at 4 weeks after the transplantation. The hCMP transplantation was associated with significant improvements in left ventricular function, infarct size, myocardial wall stress, myocardial hypertrophy, and reduced apoptosis in the periscar boarder zone myocardium. hCMP transplantation also reversed some MI-associated changes in sarcomeric regulatory protein phosphorylation. The exosomes released from the hCMP appeared to have cytoprotective properties that improved cardiomyocyte survival. CONCLUSIONS: We have fabricated a clinically relevant size of hCMP with trilineage cardiac cells derived from human induced-pluripotent stem cells. The hCMP matures in vitro during 7 days of dynamic culture. Transplantation of this type of hCMP results in significantly reduced infarct size and improvements in cardiac function that are associated with reduction in left ventricular wall stress. The hCMP treatment is not associated with significant changes in arrhythmogenicity.
引用
- Gao L, Gregorich ZR, Zhu W, et al. Large Cardiac Muscle Patches Engineered From Human Induced-Pluripotent Stem Cell-Derived Cardiac Cells Improve Recovery From Myocardial Infarction in Swine. Circulation. 2017. PMID: 29233823. doi:10.1161/CIRCULATIONAHA.117.030785
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。